Neoadjuvant therapy versus upfront resection for clinically "resectable" pancreatic cancer: The debate continues. Sarr MG, Behrns KE. Surgery 2020 Oct 13. pii: S0039-6060(20)30636.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sarr MG, Behrns KE. Neoadjuvant therapy versus upfront resection for clinically "resectable" pancreatic cancer: The debate continues. Surgery 2020 Oct 13. pii: S0039-6060(20)30636.
PMID: 33066983